👋 Hi and welcome to today’s premium edition of Venture Radar - where we uncover real businesses making real money, explore passive income opportunities, and break down ideas worth building.
Unlock 50+ founder playbooks & templates, a growing database of profitable business ideas and 2-3 premium deep dives every week
A pharmaceutical company is running a trial for a new eczema drug. They need 200 people with moderate-to-severe eczema, aged 18 to 65, not currently on biologics.
They cannot find them.
Not because those people don’t exist. There are millions. The company just has no way to reach them. So the trial sits at 40% enrolled, month after month, while the patent clock ticks and the burn rate keeps burning.
At that point somebody picks up the phone and pays an outside firm to go find those people.
Here is what that firm actually does: runs Facebook ads.
I want to be careful not to make that sound cuter than it is, because the compliance layer is real and we will get to it in detail. But strip it back and this is a paid media business with a customer who is desperate, price-insensitive, and has a hard deadline.
The numbers that make this worth reading:'
The average cost to recruit a single trial patient is over $6,500, and roughly $19,000 to replace one who drops out. (R&D Partners)
Patient recruitment is around 32% of total trial cost, the single largest cost line in the whole thing. (BioPharma Dive)
80% of trials miss their enrollment timeline, and delays can cost drug developers as much as $8 million per day. (JMIR / NIH)
50% of research sites enroll zero patients. Not “too few.” Zero. (Mordor Intelligence)
The recruitment and retention services market is around $4.49B in 2026, growing steadily, and the top five players hold only about 35% of it. (The Business Research Company, 24 Life Sciences)
That last stat is the one to sit with. Sixty-five percent of a multi-billion dollar market is not held by the giants. It is spread across specialists, boutiques, and small agencies you have never heard of.
That objection is exactly why the opportunity is still sitting there.
Yes, there are rules. Every ad gets approved before it runs, and there is one payment structure you must never use.
But the wall is paperwork, not a licence. No exam, no certification body, no registration. Nobody checks your credentials. You do not need a medical degree or a pharma CV. The rules govern what your ad says and how you get paid, not who you are.
It is about two weeks of reading. And that reading is the whole moat. Every performance marketer who sees “IRB approval required” and closes the tab is a competitor who does not exist.
This is the full operational breakdown, not a concept piece:
The exact money math, including what agencies charge, what it actually costs to acquire a patient, and where the margin sits
The four types of buyer, ranked by how realistically you can reach them in your first year, because the obvious one is the wrong one
The finder’s fee rule and the precise distinction that decides whether your pricing model is legitimate or unethical. Most people get this backwards
How to find live trials to pitch, with the specific databases and the filter method that surfaces studies that are visibly struggling
The cold outreach angle that works on research sites, plus the free audit offer that gets replies
The campaign build, from IRB submission strategy to prescreener design to the site handoff
How to structure so you never touch protected health data
Real numbers from small operators in this space, including one run by a single founder out of India
A 90-day plan and an honest list of who should not do this
Comments
Nothing yet. Say the first thing.
Sign in to join the conversation.